Active	Status	Sponsor type	Region	Phase	Filter
25 Active 4 Inactive 29 All	Not yet recruiting Recruiting Enrolling by invitation Active, not recruiting Available No longer recruiting	Industry lead sponsor Industry collaborator Coop Other	US Canada Japan Europe RoW	N/A 1 2 3 4	Highlight changes:- Show only changed items Enrollment:

Advanced Filters

25 Trials

Active Trials   

 

Export

Trial + Data / Events	Status	Ph	N	Region	Interventions	Sponsor	Conditions	Primary compl	Study compl
Ou, Sai-Hong Ignatius
KICKSTART, NCT04622007: Tomivosertib Combined With Pembrolizumab in Subjects With PD-L1 Positive NSCLC Jan 2024 - Mar 2024 : Q1'24 - Data from P2b KICKSTARTtrial in combination with Keytruda for PD-L1+ve 1L NSCLC	Active, not recruiting	2	68	US, RoW	Tomivosertib, eFT508, Pembrolizumab, Keytruda®, Pemetrexed, Alimta®	Effector Therapeutics, Medpace, Inc., ICON plc	Non-small Cell Lung Cancer	10/24	12/24
METex14, NCT04868877 / 2021-000203-20: Phase 1/2 Study Evaluating MCLA-129, a Human Anti-EGFR, Anti-c-MET Bispecific Antibody, in Advanced NSCLC and Other Solid Tumors, Alone and in Combination	Recruiting	1/2	576	Europe, US, RoW	MCLA-129, bispecific, Osimertinib, Tagrisso, Chemotherapy	Merus N.V.	Non-Small Cell Lung Cancer Metastatic, Gastric Cancer, Esophageal Squamous Cell Carcinoma, Head and Neck Squamous Cell Carcinoma, Colorectal Cancer	03/26	03/27
NCT05394831: A Phase 1/2 Study to Evaluate the Safety, Tolerability and PK of JIN-A02 in Patients With EGFR Mutant Advanced NSCLC	Recruiting	1/2	150	US, RoW	JIN-A02	J Ints Bio	EGFR Mutant Advanced Non-small Cell Lung Cancer	07/24	11/25
(MARGARET), NCT04683250: Study of RET Inhibitor TAS0953/HM06 in Patients With Advanced Solid Tumors With RET Gene Abnormalities	Recruiting	1/2	202	Japan, US	TAS0953/HM06	Helsinn Healthcare SA, ICON Clinical Research	RET-altered Non Small Cell Lung Cancer, RET-altered Solid Tumors	03/25	09/25
ARROS-1, NCT05118789 / 2021-002477-26: A Study of NVL-520 in Patients With Advanced NSCLC and Other Solid Tumors Harboring ROS1 Rearrangement	Recruiting	1/2	359	Europe, Canada, Japan, US, RoW	NVL-520	Nuvalent Inc., Nuvalent, Inc.	Locally Advanced Solid Tumor, Metastatic Solid Tumor	10/25	10/26
ALKOVE-1, NCT05384626 / 2022-000122-21: A Study of NVL-655 in Patients With Advanced NSCLC and Other Solid Tumors Harboring ALK Rearrangement or Activating ALK Mutation	Recruiting	1/2	470	Europe, Canada, Japan, US, RoW	NVL-655	Nuvalent Inc., Nuvalent, Inc.	Locally Advanced Solid Tumor, Metastatic Solid Tumor	02/26	03/26
NCT04982224: Study of REGN5093-M114 (METxMET Antibody-Drug Conjugate) in Adult Patients With Mesenchymal Epithelial Transition Factor (MET) Overexpressing Advanced Cancer	Recruiting	1/2	237	US	REGN5093-M114, Cemiplimab	Regeneron Pharmaceuticals	Advanced NSCLC	02/30	02/30
NCT04774952: Dose Escalation of RMC-5552 Monotherapy in Relapsed/Refractory Solid Tumors	Active, not recruiting	1	108	US	RMC-5552	Revolution Medicines, Inc.	Solid Tumors	03/24	03/24
Hermanowicz, Neal
NCT03515213: Safety and Efficacy of Fenofibrate as a Treatment for Huntington's Disease	Completed	2a	10	US	Fenofibrate, Placebo	University of California, Irvine	Huntington Disease	08/21	08/21
NCT05923866: A Phase 2 Study of ONO-2808 in Patients With Multiple System Atrophy	Recruiting	2	80	US	ONO-2808, Placebo	Ono Pharmaceutical Co. Ltd	Multiple System Atrophy (MSA)	08/25	08/25
Uchio, Edward
VERACITY, NCT04844749: Efficacy Evaluation of VERU-111 for mCRPC in Patients Who Have Failed at Least One Androgen Receptor Targeting Agent	Terminated	3	105	US	VERU-111, Sabizabulin, Enzalutamide, Abiraterone, XTANDI, Zytiga	Veru Inc.	Metastatic Castration-resistant Prostate Cancer, Androgen Resistant Prostatic Cancer	05/23	05/23
BOND3, NCT04452591: Study of Cretostimogene Given in Patients With Non-Muscle Invasive Bladder Cancer ,Unresponsive to Bacillus-Calmette-Guerin	Recruiting	3	190	Japan, US, RoW	Cretostimogene Grenadenorepvec, n-dodecyl-B-D-maltoside, DDM	CG Oncology, Inc.	Non Muscle Invasive Bladder Cancer, High-grade Ta/ T1 Papillary Disease Bladder Cancer	12/27	12/29
ENLIGHTED, NCT04620239 / 2020-004494-41: ENdoluminal LIGHT ActivatED Treatment of Upper Tract Urothelial Cancer () Study	Recruiting	3	100	Europe, US, RoW	padeliporfin VTP, WST11	Steba Biotech S.A., PrimeVigilance, ICON plc	Transitional Cell Cancer of Renal Pelvis and Ureter	12/24	01/29
TURBT, NCT06111235: A Study of Adjuvant Cretostimogene Grenadenorepvec for Treatment of Intermediate Risk NMIBC Following	Recruiting	3	364	Canada, US	Cretostimogene Grenadenorepvec, CG0070, n-dodecyl-B-D-maltoside, DDM	CG Oncology, Inc.	Non Muscle Invasive Bladder Cancer, Urologic Cancer, Bladder Cancer, Urothelial Carcinoma	01/28	01/30
LEGEND study, NCT04752722: LEGEND Study: EG-70 in NMIBC Patients BCG-Unresponsive and High-Risk NMIBC Incompletely Treated With BCG or BCG-Naïve	Recruiting	1/2	222	Canada, US	EG-70 (phase 1), Phase 1, EG-70 (phase 2), Phase 2	enGene, Inc.	Superficial Bladder Cancer, Non-muscle Invasive Bladder Cancer With Carcinoma in Situ	06/25	05/27
PRESERVE, NCT04972097: Pivotal Study of the NanoKnife System for the Ablation of Prostate Tissue	Active, not recruiting	N/A	121	US	Irreversible Electroporation, The NanoKnife System	Angiodynamics, Inc.	Prostate Cancer	07/24	07/24
Hermanowicz, Neal Scott
NCT01574053: Enroll -HD: A Prospective Registry Study in a Global Huntington's Disease Cohort	Recruiting	N/A	35000	Europe, Canada, US, RoW		CHDI Foundation, Inc.	Huntington's Disease	01/62	01/62
Quines, Oliver John
KICKSTART, NCT04622007: Tomivosertib Combined With Pembrolizumab in Subjects With PD-L1 Positive NSCLC Jan 2024 - Mar 2024 : Q1'24 - Data from P2b KICKSTARTtrial in combination with Keytruda for PD-L1+ve 1L NSCLC	Active, not recruiting	2	68	US, RoW	Tomivosertib, eFT508, Pembrolizumab, Keytruda®, Pemetrexed, Alimta®	Effector Therapeutics, Medpace, Inc., ICON plc	Non-small Cell Lung Cancer	10/24	12/24
BA3011-002, NCT04681131 / 2022-000135-23: CAB-AXL-ADC Safety and Efficacy Study in Adults with NSCLC	Active, not recruiting	2	240	Europe, US, RoW	CAB-AXL-ADC, BA3011, PD-1 inhibitor	BioAtla, Inc., BioAtla Inc.	Non-Small-Cell Lung Cancer	08/25	08/25
NCT04774952: Dose Escalation of RMC-5552 Monotherapy in Relapsed/Refractory Solid Tumors	Active, not recruiting	1	108	US	RMC-5552	Revolution Medicines, Inc.	Solid Tumors	03/24	03/24
Morenkova, Anna E
NCT05357989 / 2022-001542-38: A Double-blind Study to Investigate Efficacy and Safety of Buntanetap Compared With Placebo in Participants With Early PD	Completed	3	523	Europe, US	buntanetap/posiphen, Posiphen Tartrate, ANVS401, Placebo	Annovis Bio Inc., TFS Trial Form Support	Parkinson's Disease, Idiopathic	12/23	12/23
NCT01574053: Enroll -HD: A Prospective Registry Study in a Global Huntington's Disease Cohort	Recruiting	N/A	35000	Europe, Canada, US, RoW		CHDI Foundation, Inc.	Huntington's Disease	01/62	01/62
Gomez, Aleksander
NCT04994015: Parkinson's Foundation PD GENEration Genetic Registry	Recruiting	N/A	25000	Canada, US, RoW	Lab Assay for seven genetic variants for Parkinson's Disease	Parkinson's Foundation, Indiana University, Fulgent Genetics, The Parkinson Study Group	Parkinson's Disease	12/24	06/25
NCT01574053: Enroll -HD: A Prospective Registry Study in a Global Huntington's Disease Cohort	Recruiting	N/A	35000	Europe, Canada, US, RoW		CHDI Foundation, Inc.	Huntington's Disease	01/62	01/62
Anderson, Sierra
NCT01574053: Enroll -HD: A Prospective Registry Study in a Global Huntington's Disease Cohort	Recruiting	N/A	35000	Europe, Canada, US, RoW		CHDI Foundation, Inc.	Huntington's Disease	01/62	01/62